Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maureen Kenny

Executive Editor

London, UK
Maureen's expertise in bringing exclusive, business-critical content to the expanded Pink Sheet audience builds upon her many years' experience as an editor and reporter. Most recently, Maureen headed Scrip Regulatory Affairs, an indispensable publication for both pharmaceutical and medtech regulatory affairs professionals worldwide. She managed the publication's move from print to digital. Previous leadership roles also include being editor of Clinica Medtech Intelligence and acting editor of Scrip Intelligence. She chaired the DIA EuroMeeting plenary session in Paris in April 2015 and spent two years in New York covering the pharmaceutical industry in the US, Canada and, being a fluent Spanish speaker, Latin America. Maureen is based in London.
Advertisement
Set Alert for Articles By Maureen Kenny

Latest From Maureen Kenny

EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin

A new ATMP, two generics and a biosimilar got the thumbs up this week from the European Medicines Agency’s drug evaluation committee, the CHMP. The committee also recommended one product for conditional authorization and another for a pediatric use authorization, But it turned down a multiple myeloma product, and a sea squirt-based MS drug was withdrawn from the review process.

Europe Approvals

‘Outstanding Issues’ Clarified For Nine Products Nearing EU Review End – Including Neulasta Biosimilar

Ammtek, Pfizer, Portola and Roche are among the companies that will shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are nearing the end of the review pathway. Questions are also in store for the sponsor of a biosimilar version of filgrastim.

Europe Approvals

Lilly, Novartis, Jazz and Ionis Take New Products To EMA

Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.

Europe Approvals

Orphans Dominate Products Seeking End-Of-Year Joy From CHMP

Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.

Drug Review Approvals

Industry Chief Calls For “Honesty And Pragmatism” On EMA Move

Considerably fewer European Medicines Agency staff members may be willing to move with the agency to Amsterdam than is being suggested, says UK industry heavyweight Mike Thompson. Letting people stay in London and work from the EMA’s existing HQ there would help avert a potential crisis, Thompson suggests, saying what’s needed among those negotiating is honesty and pragmatism.

Europe Brexit

EMA Boss Rasi Fields Questions Over Selection Process For Agency Home Post-Brexit

A press conference following the announcement that the European Medicines Agency is to move from London to Amsterdam included a series of questions on the selection process and the voting itself.

Europe Brexit
See All
Advertisement
UsernamePublicRestriction

Register